about research careers contact
About Hua Medicine
  Hua Medicine is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action. Hua has successfully brought this compound through both Phase 1a and Phase 1b clinical trials in China with the goal of initiating Phase 2 trials by 1Q2015.
  The company has also internally developed two earlier-stage compounds focused on a clinically-validated CNS target spanning multiple indications, including potential treatments for specific neurodegenerative disorders. Hua retains world-wide rights to both its in-licensed and internally developed products.

7.31 2015
'Sea Turtle' Scientist Hunts for China's First Blockbuster Drug

7.2 2015
大公报讯:上海张江高科技园区有望成为全球"药谷"

6.20 2015
第二届代谢性疾病转化医学研讨会

6.5 2015
HMS5552的两张壁报获准在2015 ADA科学年会上展出

4.25 2015
张江药谷:打造全球生物医药"硅谷"

4.9 2015
HMS5552获准在美国开展Id期临床研究

4.6 2015
华领医药成功举办中国首个糖尿病全球原创新药第四代葡萄糖激酶激活剂 HMS5552Ⅱ期临床研究者会

3.10 2015
Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug

3.10 2015
华领医药正式向美国FDA递交新机制糖尿病创新药的临床研究申请

3.5 2015
For many of China's biotech brains-in-exile, it's time to come home

2.9 2015
Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control

2.9 2015
华领医药宣布第四代葡萄糖激酶激活剂1b期临床试验结果,显示该产品具有对糖尿病患者24小时血糖有效调控能力

1.7 2015
Hua Medicine Raises $25 Million in Series B Financing to Start Phase 2 Trials

10.23 2014
Nature 聚焦上海专栏-华领医药

8.19 2014
我国糖尿病市场现状和前景分析 生物谷

8.4 2014
New IND Process for the First in Class Drug CTA Approval at China CDE

8.4 2014
中国新机制1.1类新药临床申报和首次进人研究

5.21 2014
华领医药探索中国新药研发创新之举

4.1 2014
华领医药--糖尿病个性化治疗研究的先行者

3.26 2014
Hua Medicine tests glucokinase activator in Chinese diabetics

3.20 2014
Hua Medicine Reports Strong Results for Early Diabetes Drug Trial

3.19 2014
Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

3.19 2014
华领医药新型葡萄糖激酶激活剂项目在临床Ia实验中,成功证明了其显著的对葡萄糖控制激素释放的调节功效,正式启动在糖尿病患者中进行临床Ib研究

2.28 2014
忆张江 - 机会在中国